Posted in | News | Imaging

Integrated Diagnostics Establishes New Division to Develop PET Imaging Probes

Integrated Diagnostics (InDi) declared that it has established InDi Imaging, a new operating division that develops next-generation of PET imaging probes based on InDi’s innovative protein catalyzed capture (PCC) agent technology.

Primarily designed for in vitro molecular diagnostics, PCCs will serve as in vivo diagnostic imaging probes that imitate the properties of biologics and antibodies in PET molecular imaging and also feature synthetic small-molecules with chemically stable capability.

Along with this new launch, the company also declared that Norman Hardman, Ph.D. has been appointed as the president of InDi Imaging. Furthermore, the company reported that it has appointed the inventor of PET, Michael Phelps, Ph.D., as the advisor of InDi Imaging. InDi Dx, the other division of Integrated Diagnostics, will continue to provide vitro diagnostic medicine. The company formulated the first diagnostic blood based protein test for effectively detecting lung cancer in patients having intermediate size pulmonary nodules. This diagnostic test will be commercial launched during the first half of 2013.

The rationally designed PCCs are stable, synthetic chemical compositions having small-molecule like properties, effective for detecting designated motifs on any target protein. The detection is based on chemical diversity in the PCCs for a series of protein targets. PCCs were licensed by InDi from Caltech (California Institute of Technology). The PCC technology is based on inventions led by InDi co-founder and board member, Jim Heath, Ph.D. Under the headship of Paul Kearney, Ph.D., the company's president, the InDi team employs PCCs for in vivo diagnostic imaging applications.

PCCs were created based on ‘click chemistry,’ a process wherein researchers can click the molecular components together. Using unique stability and accuracy, it can achieve high selectivity to the target protein. InDi has earned a license from the Scripps Research Institute to use click chemistry. The company intends carrying out the first human studies of its PCC-based imaging products for another 12 to 18 months.

Disclaimer: The views expressed here are those of the author expressed in their private capacity and do not necessarily represent the views of Limited T/A AZoNetwork the owner and operator of this website. This disclaimer forms part of the Terms and conditions of use of this website.

G.P. Thomas

Written by

G.P. Thomas

Gary graduated from the University of Manchester with a first-class honours degree in Geochemistry and a Masters in Earth Sciences. After working in the Australian mining industry, Gary decided to hang up his geology boots and turn his hand to writing. When he isn't developing topical and informative content, Gary can usually be found playing his beloved guitar, or watching Aston Villa FC snatch defeat from the jaws of victory.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Thomas, G.P.. (2019, February 28). Integrated Diagnostics Establishes New Division to Develop PET Imaging Probes. AZoOptics. Retrieved on June 25, 2024 from

  • MLA

    Thomas, G.P.. "Integrated Diagnostics Establishes New Division to Develop PET Imaging Probes". AZoOptics. 25 June 2024. <>.

  • Chicago

    Thomas, G.P.. "Integrated Diagnostics Establishes New Division to Develop PET Imaging Probes". AZoOptics. (accessed June 25, 2024).

  • Harvard

    Thomas, G.P.. 2019. Integrated Diagnostics Establishes New Division to Develop PET Imaging Probes. AZoOptics, viewed 25 June 2024,

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.